Serving the Society Since 1986
Advanced Search
Volume 36 Issue 5
October 2021
    Citation: Zahra Heydarifard, Sevrin Zadheidar, Jila Yavarian, Shirin Kalantari, Ahmad Nejati, Talat Mokhtari-Azad, Nazanin Zahra Shafiei-Jandaghi. SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021 .VIROLOGICA SINICA, 2021, 36(5) : 1236-1240.  http://dx.doi.org/10.1007/s12250-021-00446-z
    shu

    SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021

    • 1.

      Virology Department, School of Public Health, Tehran University of Medical Sciences, Tehran 1417613151, Iran

    • Corresponding author: Nazanin Zahra Shafiei-Jandaghi, nz-shafiei@tums.ac.ir, ORCID: 0000-0002-6988-4321
    • Received Date: 23 December 2020
      Accepted Date: 28 June 2021
      Published Date: 30 September 2021
      Available online: 01 October 2021
    • 加载中

      1. Abduljalil JM (2020) Laboratory diagnosis of SARS-CoV-2: available approaches and limitations. New Microbes New Infect 36: 100713
          doi: 10.1016/j.nmni.2020.100713

      2. Aziz NA, Corman VM, Echterhoff AK, Müller MA, Richter A, Schmandke A, Schmidt ML, Schmidt TH, de Vries FM, Drosten C (2021) Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany. Nat Commun 12: 1-10
          doi: 10.1038/s41467-020-20314-w

      3. Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, Fry AM, Cannon DL, Chiang C-F, Gibbons A (2020) Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March 23-May 12, 2020. JAMA 180: 1576-1586

      4. He Z, Ren L, Yang J, Guo L, Feng L, Ma C, Wang X, Leng Z, Tong X, Zhou W (2021) Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. Lancet 397: 1075-1084
          doi: 10.1016/S0140-6736(21)00238-5

      5. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ, Su K, Zhang F, Gong J, Wu B, Liu XM, Li JJ, Qiu JF, Chen J, Huang AL (2020) Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 26: 1200-1204
          doi: 10.1038/s41591-020-0965-6

      6. Majiya H, Aliyu-Paiko M, Balogu VJE (2020) Seroprevalence of COVID-19 in Niger State. medRxiv. https://doi.org/10.1101/2020.08.04.20168112
          doi: 10.1101/2020.08.04.20168112

      7. Noh JY, Seo YB, Yoon JG, Seong H, Hyun H, Lee J, Lee N, Jung S, Park M-J, Song W et al. (2020) Seroprevalence of anti-SARS-CoV-2 antibodies among outpatients in southwestern Seoul, Korea. J Korean Med Sci 35: e311
          doi: 10.3346/jkms.2020.35.e311

      8. Patel R, Babady E, Theel ES, Storch GA, Pinsky BA, George KS, Smith TC, Bertuzzi S (2020) Report from the American Society for Microbiology COVID-19 international summit, 23 march 2020: value of diagnostic testing for SARS-CoV-2/COVID-19. mBio 11: e00722-20

      9. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, Sanmartín JL, Fernández-García A, Cruz I, de Larrea NF (2020) Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet 396: 535-544
          doi: 10.1016/S0140-6736(20)31483-5

      10. Poustchi H, Darvishian M, Mohammadi Z, Shayanrad A, Delavari A, Bahadorimonfared A, Eslami S, Javanmard SH, Shakiba E, Somi MH (2021) SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. Lancet Infect Dis 21: 473-481
          doi: 10.1016/S1473-3099(20)30858-6

      11. Rostami A, Sepidarkish M, Leeflang M, Riahi SM, Shiadeh MN, Esfandyari S, Mokdad AH, Hotez PJ, Gasser RB (2021) SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin Microbiol Infect 27: 331-340
          doi: 10.1016/j.cmi.2020.10.020

      12. Shakiba M, Nazemipour M, Salari A, Mehrabian F, Nazari SSH, Rezvani SM, Ghasempour Z, Heidarzadeh A, Mansournia MA (2021) Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020. Emerg Infect Dis 27: 636-638
          doi: 10.3201/eid2702.201960

      13. Vena A, Berruti M, Adessi A, Blumetti P, Brignole M, Colognato R, Gaggioli G, Giacobbe DR, Bracci-Laudiero L, Magnasco L (2020) Prevalence of antibodies to SARS-CoV-2 in Italian adults and associated risk factors. J Clin Med 9: 2780
          doi: 10.3390/jcm9092780

      14. Watson J, Richter A, Deeks JJb (2020) Testing for SARS-CoV-2 antibodies. BMJ 370: m3325

      15. Yavarian J, Shafiei-Jandaghi N-Z, Sadeghi K, Malekshahi SS, Salimi V, Nejati A, Aja-Minejad F, Ghavvami N, Saadatmand F, Mahfouzi S (2020) First Cases of SARS-CoV-2 in Iran, 2020: Case Series Report. Iran J Public Health 49: 1564

    • 加载中

    Figures(1) / Tables(1)

    PDF

    Article Metrics

    Article views(3212) PDF downloads(2) Cited by()

    Related
    Proportional views

      SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021

        Corresponding author: Nazanin Zahra Shafiei-Jandaghi, nz-shafiei@tums.ac.ir
      • 1. Virology Department, School of Public Health, Tehran University of Medical Sciences, Tehran 1417613151, Iran
      • Received Date: 23 December 2020
      • Accepted Date: 28 June 2021
      • Published Date: 30 September 2021

      Abstract: 

        HTML